Drug Approval | March 22, 2023
Zydus granted Orphan Drug Designation by USFDA for ZYIL1
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking
Subgroup analysis by HER2 expression from phase 1/2 trial of patients with HER3 expressing metastatic breast cancer highlighted in a second Presidential Session
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
MoES have identified a potent Anti-cancer molecule named GS/IICT5/6
Expands robotics to 20+ specialities
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
Patients will no longer need to travel abroad for treatment of acute cardiac diseases
Spain’s renowned centre of excellence recognises importance of verifying radiosurgery plans ahead of patient treatment
The facility has been set up to manufacture tuberculosis testing cartridges
Subscribe To Our Newsletter & Stay Updated
